CA3174729A1 - Procede de traitement d'infections liees a des dispositifs implantables - Google Patents

Procede de traitement d'infections liees a des dispositifs implantables Download PDF

Info

Publication number
CA3174729A1
CA3174729A1 CA3174729A CA3174729A CA3174729A1 CA 3174729 A1 CA3174729 A1 CA 3174729A1 CA 3174729 A CA3174729 A CA 3174729A CA 3174729 A CA3174729 A CA 3174729A CA 3174729 A1 CA3174729 A1 CA 3174729A1
Authority
CA
Canada
Prior art keywords
apt
pji
phage
infection
genomic sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174729A
Other languages
English (en)
Inventor
Subhendu BASU
Robert Hopkins
Greg Merril
Joseph FACKLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adaptive Phage Therapeutics Inc
Original Assignee
Adaptive Phage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptive Phage Therapeutics Inc filed Critical Adaptive Phage Therapeutics Inc
Publication of CA3174729A1 publication Critical patent/CA3174729A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/14—Streptococcus; Staphylococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne le domaine de la thérapie phagique et concerne en particulier la fourniture d'une composition à base de phage et un procédé de traitement ou de prévention d'infections associées à des dispositifs implantables. La composition peut être directement administrée à l'emplacement infecté du dispositif, facultativement sous la forme d'une seule dose, et/ou par d'autres modes d'administration, et peut potentiellement éviter toute exigence de remplacement du dispositif implantable.
CA3174729A 2020-04-06 2021-04-05 Procede de traitement d'infections liees a des dispositifs implantables Pending CA3174729A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063005878P 2020-04-06 2020-04-06
US63/005,878 2020-04-06
US202063039475P 2020-06-16 2020-06-16
US63/039,475 2020-06-16
PCT/US2021/025794 WO2021207082A2 (fr) 2020-04-06 2021-04-05 Procédé de traitement d'infections liées à des dispositifs implantables

Publications (1)

Publication Number Publication Date
CA3174729A1 true CA3174729A1 (fr) 2021-10-14

Family

ID=75787211

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174729A Pending CA3174729A1 (fr) 2020-04-06 2021-04-05 Procede de traitement d'infections liees a des dispositifs implantables

Country Status (5)

Country Link
EP (1) EP4132552A2 (fr)
JP (1) JP2023520583A (fr)
CN (1) CN116096390A (fr)
CA (1) CA3174729A1 (fr)
WO (1) WO2021207082A2 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100910961B1 (ko) * 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
US20120276054A1 (en) * 2011-04-28 2012-11-01 Williams Henry N Alternative bacterial treatment
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
EP3324987A4 (fr) * 2015-07-23 2018-12-26 EnBiotix, Inc. Bactériophage pour traiter des infections par un staphylococcus
WO2018126108A1 (fr) * 2016-12-29 2018-07-05 Enbiotix, Inc. Bactériophage ayant des domaines structuraux de protéine de plaque de base de reconnaissance modifiée
EP3372085A1 (fr) * 2017-03-08 2018-09-12 Pherecydes Pharma Thérapie phagique
JP2021508740A (ja) * 2018-01-02 2021-03-11 アルマタ・ファーマシューティカルズ・インコーポレーテッド Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染症を処置するための治療的バクテリオファージ組成物

Also Published As

Publication number Publication date
CN116096390A (zh) 2023-05-09
WO2021207082A2 (fr) 2021-10-14
EP4132552A2 (fr) 2023-02-15
JP2023520583A (ja) 2023-05-17
WO2021207082A3 (fr) 2021-12-02

Similar Documents

Publication Publication Date Title
Ranjbar et al. Shigella: antibiotic-resistance mechanisms and new horizons for treatment
Arias et al. The rise of the Enterococcus: beyond vancomycin resistance
US8377431B2 (en) Bacteriophage or lytic protein derived from the bacteriophage which effective for the treatment of Staphylococcus aureus biofilm
US7758856B2 (en) Bacteriophage for the treatment of bacterial biofilms
JP2021522857A (ja) 標的細菌を死滅させるための方法および組成物
JP2018023367A (ja) 転写因子デコイ
JP2021505197A (ja) 微生物感染を防ぐための方法および組成物
EP3996510A2 (fr) Compositions biothérapeutiques vivantes et procédés
De Mobile genetic elements of Vibrio cholerae and the evolution of its antimicrobial resistance
Mancuso et al. Bacterial antibiotic resistance: The most critical pathogens. Pathogens 2021, 10, 1310
Lahiri et al. Biofilm and antimicrobial resistance
Martínez Mechanisms of action and of resistance to quinolones
CA3174729A1 (fr) Procede de traitement d'infections liees a des dispositifs implantables
JP2022536068A (ja) クレブシエラの制御のためのクレビシン
Yang et al. Biofilm tolerance, resistance and infections increasing threat of public health
US20240016855A1 (en) Targeted-antibacterial-plasmids combining conjugation and crispr/cas systems and uses thereof
Chen et al. Recent advances in peptide nucleic acids as antibacterial agents
Bleriot et al. Improving phage therapy by evasion of phage resistance mechanisms
WO2016146037A1 (fr) Inhibiteur utilisé pour inhiber/désintégrer un biofilm, et application correspondante
Jolivet‐Gougeon et al. Bacterial Persistence in Biofilms and Antibiotics: Mechanisms Involved
TW202122585A (zh) 治療細菌感染的方法
Wilkinson Biofilm formation and antibiotic resistance on alginate beads, of Staphylococcus aureus and other health care associated bacterial species
Puca et al. Biofilm and bacterial membrane vesicles: recent advances
Hossain Molecular Interactions between phage and the catfish pathogen Edwardsiella ictaluri and Comparative Genomics of Epidemic strains of Aeromonas hydrophila
Lewis et al. Isolation of a Novel Jumbo Bacteriophage Effective Against.